Osanetant (SR-142,801) was a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which was being researched for the treatment of schizophrenia, but was discontinued. It was the first non-peptide NK3 antagonist developed in the mid-1990s, Other potential applications for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.
^Kamali, F (July 2001). "Osanetant Sanofi-Synthélabo". Current opinion in investigational drugs (London, England : 2000)2 (7): 950–6. PMID11757797.
^Emonds-Alt, X; Bichon, D; Ducoux, JP; Heaulme, M; Miloux, B; Poncelet, M; Proietto, V; Van Broeck, D et al. (1995). "SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor.". Life Sciences56 (1): PL27–32. doi:10.1016/0024-3205(94)00413-M. PMID7830490.|displayauthors= suggested (help)
^Desouzasilva, M; Mellojr, E; Muller, C; Jocham, G; Maior, R; Huston, J; Tomaz, C; Barros, M (May 2006). "The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys". European Journal of Pharmacology536 (3): 269–78. doi:10.1016/j.ejphar.2006.03.010. PMID16603151.
^Jocham, Gerhard; Lezoch, Katharina; Müller, Christian P.; Kart-Teke, Emriye; Huston, Joseph P.; De Souza Silva, M. AngéLica (September 2006). "Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core". European Journal of Neuroscience24 (6): 1721–32. doi:10.1111/j.1460-9568.2006.05041.x. PMID17004936.